“Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s5. doi:10.25251/skin.1.supp.4.